ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EKF Ekf Diagnostics Holdings Plc

27.40
-0.70 (-2.49%)
Last Updated: 16:18:33
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Ekf Diagnostics Holdings Plc EKF London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.70 -2.49% 27.40 16:18:33
Open Price Low Price High Price Close Price Previous Close
28.70 27.00 28.70 28.10
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Ekf Diagnostics EKF Dividends History

Announcement Date Type Currency Dividend Amount Ex Date Record Date Payment Date
28/03/2023FinalGBP0.01202/11/202303/11/202301/12/2023
29/03/2022FinalGBP0.01203/11/202204/11/202201/12/2022
29/03/2022InterimGBP0.01203/11/202204/11/202201/12/2022
30/03/2021FinalGBP0.01104/11/202105/11/202101/12/2021
15/07/2019InterimGBP0.0116/11/202017/11/202001/12/2020
15/07/2019FinalGBP0.0105/11/202006/11/202001/12/2020

Top Dividend Posts

Top Posts
Posted at 16/2/2024 09:35 by wan
Following on from my post 3214 regarding Beta-Hydroxybutyrate (B-HB) use in the diagnosis of Diabetic Ketoacidosis (DKA)and the a possible association with GLP-1 receptor agonist therapies such as Wygovy. There are apparently some risk of DKA from the weight loss drugs, but directly triggering DKA is relatively rare. However, I note that UK's NICE guides to not prescribe GLP-1 receptor agonist to people with Ketoacidosis (DKA), which implies that a test is required to confirm otherwise. Therefore given GLP-1 receptor agonist runaway demand (increasing prescription and non-prescription use), then B-HB testing is likely to accordingly increase too.

The other factor I looked at was the widely prescribed diabetic drugs SGLT-2 inhibitors, a medication used to treat type 2 diabetes by lowering high blood glucose levels (Market size is estimated at north of USD 11.42 billion in 2024, and is expected to reach USD 17.32 billion by 2029 Source: hxxps://www.mordorintelligence.com/industry-reports/sglt-2-market)

And whilst DKA is traditionally associated with Type 1 diabetes, it is increasingly recognised in Type 2 diabetes, particularly with the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, thereby requiring diagnosis and monitoring -

Cureus part of Springer Nature Group
Kripa Tiwari • Nava R. Sharma • Madalasa Pokhrel • Arjun Basnet • Michael Kaplan
Published: November 25, 2023
DOI: 10.7759/cureus.49402

Diabetic ketoacidosis (DKA) is a severe metabolic emergency characterized by hyperglycemia, ketosis, and metabolic acidosis, which has traditionally been associated with individuals diagnosed with Type 1 diabetes [1]. However, there is a growing recognition of its occurrence in individuals with Type 2 diabetes, primarily because of the increased use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors [1]. These medications, mainly prescribed for the management of Type 2 diabetes, have led to a notable increase in the incidence of DKA, with a particular focus on euglycemic DKA, a distinct presentation marked by blood glucose levels within the normal range. Empagliflozin, a well-known SGLT-2 inhibitor, has demonstrated significant advantages in glycemic control and cardiovascular outcomes for individuals with Type 2 diabetes [2].

However, there is a growing concern regarding the potential of SGLT-2 inhibitors to induce DKA, including the euglycemic variant. Despite ongoing research, the precise mechanisms responsible for this phenomenon remain incompletely understood.



In short, B-HB testing is likely to experience continued growth and become a very large market. And on the face of it, it could be on a relatively steep growth curve due to the increased use of certain drugs highlighted above. Indeed EKF recently recorded 27% year-on-year increase in B-HB sales.

The increasing incidence of DKA in both type 1 and type 2 diabetes and the resulting increase in testing requirements, including multiple individual testing (monitoring), will likely (unfortunately) continue to drive growth in EKF's B-HB sales.

And as I stated in post 3214 above 'According to EKF, B-HB remains an opportunity for significant growth once new fermentation capacity comes online, which suggests that a key strategic consideration was for some of the new fermentation capacity to be allocated to the increased production of B-HB'.

Therefore, and strictly in my view, there is an increasing likelihood for announcements of further strategic partnerships, and distribution agreements.

But of course readers should make up their own minds and conduct their own research etc.
Posted at 31/1/2024 13:04 by wan
I note the reported good progress in Life Sciences fermentation expansion, purchase orders received, and the onboarding of a number of customers etc. But I get the impression that the recent Trading Update was a bit short on the detail that most were hoping for (Rome wasn't built is a day), but I note that further insight on 2024 will be provided at the time of the FY Results in late March (not that long to wait!).

It might therefore be useful to read the recent Trading Update (TU) in the context of the following announcement back in October 2023 regarding the opening of EKF's new US Life Sciences Manufacturing Facility:

EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical and industrial applications. The Company is at the forefront of supporting life sciences global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver breakthrough discoveries and advancements in healthcare and medicine.

The Company's state-of-the-art facilities and leading technical expertise in specialist enzyme production uses precision microbial fermentation and cutting-edge downstream processes, to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications.

The new 24,000 square foot state-of-the-art facility addresses a significant gap in the US market for mid-volume manufacturing and will enable EKF to meet the increasing demands of its growing customer base. As part of its investment programme, EKF has installed 10L, 65L, 300L, 1,500L, 3,000L and 14,500L units as well as key upstream and downstream process capabilities at its South Bend plant. The cutting-edge, intelligent design of the Group's modular platform includes bioreactors ranging from 5L to 14,500L to enable it to deliver an end-to-end service from bench/proof-of-concept through to full scale commercial production. This efficient and scalable platform allows multiple batch cycles to run in parallel, enabling greater process control and precision to deliver effectively the desired yields.

The South Bend site is currently operating with full fermentation capabilities and is also expected to have all downstream processing capabilities fully operational by December 2023. As previously announced, the Company has already received the first purchase order for precision fermentation services for the new facility and has a strong contract pipeline, with onboarding underway for a number of existing OEM customers and the potential to develop into long-term strategic partnerships. During 2024, the Company expects to see a steady build-up of revenues generated from this new capacity and, as contracts scale-up, EKF Life Sciences is expected to deliver substantial, long-term sustainable growth.

The South Bend site is located in close proximity to the Company's existing 20,000 square foot facility in Elkhart. Both sites operate to the highest regulatory standards under cGMP (current Good Manufacturing Principles), ISO 9001 and ISO 13485 Quality Program.
Full RNS -

The fact that EKF's global websites only show the contract fermentation capacity offered by the existing Elkhart facility(maximum capacity 1600 litre vessel), one assumes that that could imply that the "increasing demands of its growing customer base" and "strong contract pipeline"(both referred to above) will be utilising the new increased capacity to such an extent that highlighting the new capacity on their websites is currently not a priority.

Conversely, it could mean that the new capacity is not fully operational, but that's not what the TU or opening announcement stated, and the use of plurals with regard to both purchase orders and onboarding of customers in the TU, with the broker (Singer Capital Markets) stating that "new customers onboarding into the Life Sciences fermentation plant, after the site opened in Q4." implying that good progress is indeed continuing to be made.

I therefore remain more than hopeful that further investor patience will be duly rewarded.
Posted at 29/1/2024 09:41 by wan
Good to learn from todays Trading Update that growth in Point of Care and BHB sales has proven resilient in 2023, and that growth is predictable in 2024 too.

With EKF's existing fermentation facility offering development and tech transfer, and with the new facility offering a significant increase in relatively scarce capacity via state-of-the-art fermenters, fermentation suites, and downstream processing, EKF are well placed to meet the growing demand for novel ingredients with product-enhancing properties, and the need for security of supply.

Therefore, with the new capacity in fermentation coming on stream, and with purchase orders received, and the continuation of the onboarding of customers for the new precision fermentation, it is very encouraging, as precision fermentation is set to provide an important platform for sustainable long-term growth.
Posted at 23/12/2023 10:34 by wan
Staying with what's relevant....

EKF's core established business, with leading products and services, and good rates of organic growth, is clearly valuable (which some might value greater than others). But with the capacity expansion, and I would add: innovative biotechnology solutions, at the new South Bend facility nearing completion, there is very good reason to be optimistic about future rates of growth beyond the organic growth being delivered from the core business.

There will no doubt be those that are in no rush to invest ("wade in"), and I respect the reasons for that (plus it's part and parcel of the market). But clearly some investors, myself included, have chosen to take advantage of EKF's overly depressed share price(I get why this has happened btw, and it's a personal matter of judgement as to whether that has gone too far, or otherwise etc).

In terms of fermentation, one area that has been catching my attention over the last few months, is how much more critical the downstream processing is becoming and indeed has become, and as we know, the increase in customer needs for downstream processing was a significant factor that pushed scale-up revenues from the new facility into 2024.

From various validated sources: most of the biggest and most successful improvements in productivity to date have been delivered in the upstream processes (like fermentation), and it is now the downstream process that is receiving more attention and becoming even more critical with new technology and methods being deployed, and in many cases it is apparently where the differentiation and real value is created (for the manufacturer and the customer).

And although it has taken longer than originally guided (recall that customer needs for downstream processing became apparent, and no doubt played its part in the delay), it may be underappreciated that EKF will have installed 'cutting-edge downstream processes' to address the increasingly critical processing needs.

Current guidance: The South Bend site is currently operating with full fermentation capabilities and is also expected to have all downstream processing capabilities fully operational by December 2023.

And as I stated in post 3196, "Time, and obviously updates from EKF, will tell"

Suffice to recap the following though:

EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical and industrial applications. The Company is at the forefront of supporting life sciences global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver breakthrough discoveries and advancements in healthcare and medicine.

The Company's state-of-the-art facilities and leading technical expertise in specialist enzyme production uses precision microbial fermentation and cutting-edge downstream processes, to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications.

The new 24,000 square foot state-of-the-art facility addresses a significant gap in the US market for mid-volume manufacturing and will enable EKF to meet the increasing demands of its growing customer base. As part of its investment programme, EKF has installed 10L, 65L, 300L, 1,500L, 3,000L and 14,500L units as well as key upstream and downstream process capabilities at its South Bend plant. The cutting-edge, intelligent design of the Group's modular platform includes bioreactors ranging from 5L to 14,500L to enable it to deliver an end-to-end service from bench/proof-of-concept through to full scale commercial production. This efficient and scalable platform allows multiple batch cycles to run in parallel, enabling greater process control and precision to deliver effectively the desired yields.
(END)

Please conduct your own research when making investment decisions etc, as the originator, or the threads contributors, could be either wrong or inaccurate.
Posted at 30/8/2023 17:05 by wan
Yes, it perhaps does well to not raise expectations too high.

But it's perhaps also worth recalling that EKF's established Life Science division recorded 60% year-on-year growth in 2022, and EKF's enhanced fermentation offering has already received high demand, with the Executive Chair stating that Life Sciences fermentation investment is "offering the potential for significant revenue growth beyond current conservative guidance". Time will tell!

From the AR - Our Life Sciences division grew by 60% to £3.2m (2021: £2.0m). We believe that this is a highly-scalable business unit, where we can take advantage of a demand-driven opportunity to produce research and diagnostic enzymes in the molecular and clinical chemistry markets, and in industrial and agricultural enzymes settings as well as food grade fermentation digestive proteins. Our production expansion is for customers that we have established relationships with, and who are well advanced in the process of transferring to our enzyme contract manufacturing services delivered from our two US sites in Indiana.
(END)

We were previously guided that a range of large companies are set to utilise EKF's fermentation capabilities and increased capacity. For example EKF are involved in producing biological enzymes for use in agriculture, which is an area that I have previously investigated and researched (not EKF), but it is something that I have recently taken a 'specific' and closer look at.

In the meantime, I am particularly keen to learn who will fill the role of CEO.
Posted at 24/7/2023 08:42 by wan
Food for thought:

Back in March, and without the upside from the new fermentation facility, EKF's 2023 revenue was forecast at £57m (of which around £40m is recurring revenue) with EBITDA forecast at £14.1m, which according to my math, and based on EKF's current valuation, results in an EBITDA multiple of 8.7 X

Although last week EKF closed 18.40% above the 52 week low of 23.10p set on May 18, 2023 (source FT.com), the shares have recently pulled back to a similar level in share price terms to that in March 2023, when (according to the Executive Chairman) EKF was being valued at 7 x 2024 EBITDA. Most would put that pullback down to the recent uncertainty surrounding the moves and change at board level.

Assuming that the performance and prospects for the business have not materially deteriorated, if that type of undervaluation/underappreciation persists beyond the anticipated results, and given how the US rates and values businesses compared to the UK, then perhaps a US listing might become a nearer term reality. In the US, companies such as EKF that can forecast and deliver profitable growth, has a high level of recurring revenue, pays a dividend, and has no long term debt, would likely be rated far more highly.

Although the link further below does not include microcaps etc, it provides at least some guidance and highlights the gaping difference between the US and the UK in terms of equity valuations.

In terms of industry/sector, EKF spans across Life Sciences Tools and Services, and Health Care Equipment and Supplies. According to Interpath, both of these industry/sectors are rated in the top 10 in terms of EBITDA multiples in the US, at 18.62 X and 17.56 X respectively, giving an average of 18X. In the UK, Health Care is pegged at 7.33 X and appears to be based only on pharmaceuticals (again highlighting an important difference).

Readers can apply what they think is an appropriate multiple and do the maths using EBITDA of £14.1m for 2023 and circa £18m for 2024 in order to arrive at a notional/potential market capitalisation, and the same with regard to a notional/potential share price (in round figures, EKF has 455m shares in issue).

Although the following does not include microcaps or AIM stocks etc, it provides at least some guidance as to the gaping difference from a sophisticated comparison of sector and industry on how UK and US companies are valued, and highlights the material difference between the US and the UK in terms of valuation multiples for industry/sectors -

Interpath
Valuation Multiples by Industry 24 May 2023



In any regard, the difference is notable, and no wonder then that the UK is fertile hunting ground for US companies! And perhaps highlighting the apparent threats to, or the assumption that the UK holds a leading position as a global and vibrant financial centre (although reforms are afoot aimed at making London a more attractive place to list).

In the meantime, the Trading Update may well provide some guidance as to how far out, or not, the market is in terms of valuing EKF's persistent, reliable recurring revenues, and its significant growth prospects.
Posted at 18/5/2023 07:16 by wan
As promised, a few snippets of information from quickly taken notes during the AGM (albeit that audible transmission during the meeting was not always perfect). I may add more detail if I have missed anything amongst my scrawled notes! -

Russia: Accessing the dividend being held in Russia is still problematic. However, EKF are still selling diagnostics to Russia (essential medical diagnostics are allowed), but at significantly increased prices with upfront payment, resulting in the amount of cash under restriction not growing. EKF are routinely taking legal advice as the situation re sanctions is constantly changing.

Veterinary lactate testing is currently a small percentage of sales, but there is real utility and demand, and therefore sales will likely increase over time. EKF now has in-house veterinary expertise/sales capabilities to address the opportunity (previously not in place).

Artificial intelligence (AI) is being used to develop the enzymes that EKF manufacture, and includes CRISPR 9 enzyme manufacturing for use in molecular diagnostics. For context, it is considered by some experts that CRISPR-based diagnostics could reshape the field of point-of-care molecular diagnostics (Julian described a CRISPR based diagnostic as incredible (or something like that). Readers may recall that EKF highlighted in a recent presentation that molecular enzymes will be manufactured for both third party OEM, and EKF brand.

AI optimises the fermentation process ultimately unlocking even more potential from precision fermentation and creating refined, differentiated products across a range of markets, including pharmaceutical, diagnostics, food, and food production.

A range of large companies are set to utilise in EKF's fermentation capabilities and capacity, for example EKF are involved in producing biological enzymes for use in agriculture.

EKF's Elkhart fermentation facility will serve as an important R&D hub ahead of advancing projects to scaled-up production.

Julian Baines, in describing the level of demand for EKF's enhanced fermentation offering, said that 'he had never seen this level of enquiries in my career', and further stated that 2024 is looking to be very successful with the investment in fermentation capacity and capabilities offering shareholders the biggest growth opportunity in 10 years.

The COVID pandemic has changed our relationship and familiarity with at-home testing. Point of care testing in the UK got a mention during the AGM, in terms of the potential from testing at home and at pharmacies. See today's news below from MyHealthChecked (an EKF customer).
Posted at 27/3/2023 14:02 by wan
As I stated previously (in post 3021), I appreciate that a reset was inevitable post the Trading Update in February this year, but despite considerable growth in the established core businesses compared to pre-pandemic levels, in share price terms EKF is back to pre-pandemic levels when both the FY revenue in 2019 (£44.9m) and the growth prospects for the core business were materially less than they are today.
(END)

And whilst I appreciate the frustration and the fact that the market can over-react in both directions, suggestions that the shares could hit 16p and even 10p appear delusional/scaremongering (and perhaps wishful thinking by some). Time will tell!

Whilst ADL has not been a successful investment (of EKF's time and money), it was always non-core, but some have interpreted that the cash EKF has generated to date has been blown. However, given the planned investments made during the year, including the significant capital expenditure to increase EKF's enzyme fermentation capacity in the US, that assumption, at this stage at least, appears 'wildly' overstated!

The current share price weakness is increasingly looking too harsh, and recently resulted in EKF's broker describing its shares as being in "deep value territory and offer a strong buying opportunity". However, I understand and respect that the current uncertainty will hold the shares back until we get further clarity and vision, which is likely to come tomorrow. In short, I don't think investors will have to wait too long for a re-rating of EKF's shares, as meaningful contract news will also surely emerge.

Staying with meaningful contracts, recall that EKF signed an exclusive, multi-million dollar agreement with Oragenics, Inc., a Florida-based biopharmaceutical company, for the manufacturing of Oragenics' lantibiotic bulk drug substances in the United States. Under the collaboration agreement, EKF Diagnostics will manufacture compounds intended for preclinical and early-stage clinical trials, which along with other projects were paused as a result of COVID-19. I noted recently that Oragenics Lantibiotic project has made further progress -

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

March 14, 2023
Potentially Addresses Life-Threatening Antibiotic-Resistant Infections

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party laboratory testing of several compounds in Oragenics’ lantibiotics platform to combat multiple pathogens despite the resistance of those pathogens to standard-of-care antibiotics. Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.

Kim Murphy, President and Chief Executive Officer of Oragenics, commented, “We previously reported that cross-resistance does not appear to emerge with our novel class of antibiotics because of their unique mechanism of action. We are encouraged by the outcomes of our recent collaboration with Linnaeus, which verify that life-threatening pathogens that are resistant to drugs of last resort – including vancomycin and daptomycin – remain sensitive to several of our lantibiotic compounds. This is another significant step in efforts to identify a new lead compound to advance into the clinic toward the development of novel therapies to fight infectious diseases."


Thus, I remain patiently invested and having also added to my position at recent lows (prior to the recent broker note).
Posted at 01/11/2022 15:05 by wan
Heads-up via Walbrook PR -

EKF to showcase POCT connectivity solutions at MEDICA 2022
1st November 2022

Powerful digital connectivity products and contract manufacturing capabilities in Hall 3 at Stand B69

EKF Diagnostics, a global diagnostics company, will be introducing its latest product developments and offerings at MEDICA 2022, Düsseldorf, Germany, 14-17 November. Highlighted at the event will be its newly introduced point-of-care testing (POCT) connectivity solutions, including the enhanced DiaSpect Tm hand-held hemoglobin analyzer and the new EKF Link digital connectivity software. In addition to its POCT products, EKF will also highlight its growing contract manufacturing services to the healthcare industry.

In Hall 3 at Stand B69, the EKF team will be available to demonstrate how its new state-of-the-art EKF Link middleware enables healthcare providers to readily manage their POC analyzers and all generated data via one centralized platform. An intuitive, open solution, EKF Link can be interfaced to most vendor’s POC analyzers, in addition to EKF’s own portfolio. This facilitates real-time remote management and secure transfer of data, including patient test results, QC results, operator management and analyzer configuration within a range of healthcare settings.

Adding to the ever-growing list of POC analyzers that are compatible with EKF Link, the enhanced DiaSpect Tm hemoglobin analyzer now offers calculated hematocrit values, and its rapid test results can be securely sent to centralized Laboratory Information Systems (LIS) or Patient Information Systems (PIS). The palm-sized analyzer’s new digital connectivity capabilities enabled by EKF Link also allows authorized users to easily access its near-patient results through a web browser, whatever their location, supporting seamless patient care.

EKF will also be highlighting its global contract manufacturing capabilities covering configuration of product, sourcing materials, providing state-of-the-art bulk formulation and dispensing facilities, through to services such as kitting, labelling and packaging. With extensive facilities in the USA, UK and Germany, EKF has a proven track record of developing and manufacturing quality products for a range of markets, industries, and businesses - from start-ups to industry leaders – across the globe.

MEDICA 2022 brings together industry leaders, global healthtech professionals, start-ups and experienced high-tech products in the medical technology arena.

Discussing how EKF’s contract manufacturing team has supported his start-up health technology company, Elliot Quigley, Project Manager, Proton Dx, said: “EKF Diagnostics has been instrumental in our development as a company. They worked above and beyond their remit to ensure the successful completion of our pivotal milestones. They worked closely with our team to provide solutions and guidance navigating the tricky start-up landscape, whilst providing top-tier products.”

Mike Salter, CEO, EKF Diagnostics, said: “We look forward to welcoming visitors to our stand at MEDICA where our team of product and contract manufacturing specialists will be on hand to discuss our broad range of medical diagnostics products and manufacturing services. We are particularly excited to be able to demonstrate our enhanced capabilities in POCT connectivity which provides hospitals, laboratories and clinicians with the ability to manage and evaluate their patient and user data easily and securely.”
Posted at 01/7/2022 13:23 by wan
'On plan' news -

Industry News: EKF to highlight specific glycemic control marker at AACC 2022
EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637
30 Jun 2022

EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients.

Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material.

“The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics.

Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations.

EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely.

EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities.


Recall from the EKF Link RNS -

The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies.

Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data.

"This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities."

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com